Innohep

Tinzaparin sodium, the active ingredient in Innohep, is a low molecular weight heparin presented as a sterile solution for subcutaneous, intravenous, and haemodialysis use. It is employed to prevent and treat venous thromboembolism in adult patients at risk.

GNH USA supplies Innohep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Innohep (tinzaparin sodium) is used in the venous thromboembolism pathway to prevent and manage clot formation. - Deep vein thrombosis (prevention): reduces incidence of clot formation in at‑risk patients. - Deep vein thrombosis (treatment): facilitates resolution of existing thrombi and prevents extension. - Pulmonary embolism (prevention): lowers risk of embolic events in patients with DVT or other risk factors. - Haemodialysis (anticoagulation): provides anticoagulant support during extracorporeal dialysis circuits.

Tinzaparin sodium may be associated with bleeding‑related and immune‑mediated reactions.

Common Side Effects: - Injection site pain or erythema. - Minor bruising or hematoma at the injection site. - Mild gastrointestinal bleeding. - Transient thrombocytopenia. - Elevated liver enzymes.

Serious or Rare Side Effects: - Major hemorrhage (intracranial, gastrointestinal). - Heparin‑induced thrombocytopenia (HIT) with paradoxical thrombosis. - Spinal or epidural hematoma. - Severe allergic reaction (anaphylaxis). - Disseminated intravascular coagulation (rare).

When prescribing Innohep, clinicians should evaluate patient‑specific risk factors and monitor therapy closely. - Renal impairment: assess dosing and monitor anti‑Xa levels. - History of bleeding: weigh benefits against increased bleeding risk. - Concurrent anticoagulants or antiplatelet agents: avoid or adjust therapy to limit bleeding. - Pregnancy: use only if potential benefit justifies potential risk to fetus. - Upcoming surgery or invasive procedures: discontinue according to clinical guidelines. - Store at ambient temperature: keep in original container, protect from moisture and light.

Tinzaparin sodium can interact with several agents that affect hemostasis or drug metabolism.

Major Interactions (Avoid): - Other parenteral anticoagulants (e.g., unfractionated heparin, fondaparinux): additive anticoagulant effect. - Direct thrombin inhibitors (e.g., dabigatran): increased bleeding risk. - Thrombolytic agents (e.g., alteplase): synergistic hemorrhagic potential.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may exacerbate gastrointestinal bleeding. - Selective serotonin reuptake inhibitors (SSRIs) or SNRIs: heightened bleeding tendency. - Corticosteroids: potential for mucosal bleeding. - ACE inhibitors: rare reports of enhanced anticoagulant effect.